BioSpace News Archive

In November 2020, the Minister of Health announced an independent panel would pursue the review of the Public Health Agency of Canada’s Global Public Health Intelligence Network.

Strongbridge Recently Submitted a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the U.S. Food & Drug Administration

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that new data, demonstrating the positive effect of tesamorelin on the circulation of immune activation markers associated with liver inflammation, was presented at The Endocrine Society’s annual meeting, ENDO 2021.

BioMarin Pharmaceutical Inc. announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University of Melbourne, Parkville, Victoria.

Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse eventsin Phase 2 and Phase 3 studies in POMC, PCSK1, or LEPR deficiency showing consistent safety results for setmelanotide

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced positive results from the first pivotal trial for the Omnipod® 5 Automated Insulin Delivery System.

Normalization of Blood Calcium and Urine Calcium in 6 of 6 (100%) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Participants Initially Evaluated Over 5 Days Demonstrates Proof-of-Concept

Neurocrine Biosciences, Inc. announced that it will present additional positive data from its Phase II CAHlibrate study of crinecerfont, an investigational, oral, non-steroidal corticotropin-releasing factor type 1 receptor antagonist for the potential treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, at ENDO 2021, the Endocrine Society’s annual meeting, on March 20–23, 2021.

Core One Labs Inc., is pleased to announce that it has filed an application to list its common shares on the Capital Market tier of The NASDAQ Stock Market LLC.

Data show greater GH response in pediatric growth hormone deficiency (PGHD) from LUM-201 than standard GH secretagogues